Sai-Hong I. Ou, MD

• Lung Cancer Services
• Medical Oncology Services
• Hematology Oncology Services
• Cancer Services

• American Board of Internal Medicine, Hematology
• American Board of Internal Medicine, Internal Medicine
• American Board of Internal Medicine, Medical Oncology

• English
• Cantonese
• Mandarin

• Professor — Division of Hematology/Oncology, Department of Medicine, UCI School of Medicine
• Hamoui Salous Endowed Chair for Thoracic Oncology Research
• Editor-in-Chief — Lung Cancer: Targets and Therapy
• Associate Editor — Journal of Thoracic Oncology

• Best Doctors in America® (Medical Oncology and Hematology), 2011-2013
• Young Investigator Award — Southwest Oncology Group (SWOG)

Dr. Sai-Hong I. Ou is board-certified UCI Health medical oncologist who specializes in the diagnosis and treatment of lung and thyroid cancers. He is an internationally renowned expert in targeted therapies for lung cancers.

He earned his medical degree at the University of Texas Southwestern Medical School in Dallas, followed by an internship and residency in internal medicine at Duke University School of Medicine in Durham, N.C. He received fellowship training in hematology/oncology at Beth Israel Deaconess Hospital in Boston, Mass. He also holds a PhD in cellular and molecular biology from the University of Texas Southwestern Medical Center in Dallas.

Ou is the author of more than 180 peer-reviewed manuscripts that have appeared in the New England Journal of Medicine, Lancet Oncology, the Journal of Clinical Oncology, Cancer Discovery and Nature Medicine, primarily about targeted therapies for lung cancer and resistance mechanisms.

He has conducted numerous early phase clinical trials that have advanced the standard of treatment for lung cancer care. In particular, he is one of the seven original principal investigators for a phase 1 clinical trial that led to the approval of crizotinib for the treatment of certain non-small cell lung cancers (NSCLC). His research also led to the approval of afatinib to treat certain NSCLCs. He also is actively collaborating with sequencing companies to mine data about resistance mechanisms, treatment outcomes to targeted therapy and rare actionable driver mutations.

Ou, the Hamoui Salous Endowed Chair for Thoracic Oncology Research, serves as editor-in-chief of Lung Cancer: Targets and Therapy and associate editor of the Journal of Thoracic Oncology. He is also an editorial board member for the Annals of Oncology, Critical Reviews in Oncology/Hematology, Clinical Lung Cancer and Translational Lung Cancer Research.

He sees patients at the UCI Health Chao Family Comprehensive Cancer Center in Orange.

View this physician's faculty profile ›

Speakers Bureau Topics

• ALK Positive Tumors (including lung cancer)
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Lung Cancer in the Never Smoker
• Lung Cancer Staging
• Lung Cancer, New Driver Mutations
• Lung Cancer, The Era of Molecularly Targeted Therapy
• Molecular Profiling in Gastric and Cholangiocarcinoma Cancer
• Nasopharyngeal Carcinoma
• Non-Small Cell Lung Cancer
• Second Generation Epidermal Growth Factor Receptor Inhibitor
• Small Cell Lung Cancer
• Stomach Cancer